ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,266.95
-0.74%
Dow Jones
38,441.54
-1.06%
US Dollar vs MXN
16.9903
1.15%
Brent Oil
83.375
-1.13%
Bitcoin
67,648.71
-0.94%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. MiNK Therapeutics Inc (INKT)

  7. MiNK Therapeutics Inc (INKT) Noticias

INKT

MiNK Therapeutics (INKT)

MiNK Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:INKT
FechaHoraFuenteTítuloSímboloCompañía
22/05/202415:33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:INKTMiNK Therapeutics Inc
22/05/202406:30GlobeNewswire Inc.MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual MeetingNASDAQ:INKTMiNK Therapeutics Inc
16/05/202407:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INKTMiNK Therapeutics Inc
14/05/202406:30GlobeNewswire Inc.MiNK Reports First Quarter 2024 ResultsNASDAQ:INKTMiNK Therapeutics Inc
14/05/202406:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INKTMiNK Therapeutics Inc
13/05/202406:30GlobeNewswire Inc.MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board ObserverNASDAQ:INKTMiNK Therapeutics Inc
30/04/202406:30GlobeNewswire Inc.MiNK to Provide Corporate Update and First Quarter 2024 Financial ReportNASDAQ:INKTMiNK Therapeutics Inc
08/04/202411:00GlobeNewswire Inc.MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACRNASDAQ:INKTMiNK Therapeutics Inc
21/03/202406:26IH Market NewsU.S. Index Futures Rise as Fed’s Dovish Outlook Spurs Positive Investor Sentiment; Oil Prices See Minor DeclinesNASDAQ:INKTMiNK Therapeutics Inc
21/03/202406:00GlobeNewswire Inc.MiNK Reports Fourth Quarter and Year-End 2023 ResultsNASDAQ:INKTMiNK Therapeutics Inc
07/03/202406:30GlobeNewswire Inc.MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial ReportNASDAQ:INKTMiNK Therapeutics Inc
05/03/202417:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INKTMiNK Therapeutics Inc
14/02/202407:00GlobeNewswire Inc.First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and BalstilimabNASDAQ:INKTMiNK Therapeutics Inc
06/02/202407:00GlobeNewswire Inc.MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature CommunicationsNASDAQ:INKTMiNK Therapeutics Inc
30/01/202407:00GlobeNewswire Inc.MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in OncogeneNASDAQ:INKTMiNK Therapeutics Inc
20/12/202306:30GlobeNewswire Inc.ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic DevelopmentNASDAQ:INKTMiNK Therapeutics Inc
09/11/202306:00GlobeNewswire Inc.MiNK Therapeutics Reports Third Quarter 2023 ResultsNASDAQ:INKTMiNK Therapeutics Inc
03/11/202311:00GlobeNewswire Inc.MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023NASDAQ:INKTMiNK Therapeutics Inc
30/10/202307:00GlobeNewswire Inc.MiNK to Provide Third Quarter 2023 Financial Report and Corporate UpdateNASDAQ:INKTMiNK Therapeutics Inc
27/09/202308:05GlobeNewswire Inc.MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023NASDAQ:INKTMiNK Therapeutics Inc
24/08/202307:30GlobeNewswire Inc.MiNK Therapeutics to Participate in September Investor ConferencesNASDAQ:INKTMiNK Therapeutics Inc
11/08/202306:44Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INKTMiNK Therapeutics Inc
10/08/202306:30GlobeNewswire Inc.MiNK Therapeutics Reports Second Quarter 2023 ResultsNASDAQ:INKTMiNK Therapeutics Inc
28/07/202307:30GlobeNewswire Inc.MiNK to Provide Second Quarter 2023 Financial Report and Corporate UpdateNASDAQ:INKTMiNK Therapeutics Inc
05/06/202306:30GlobeNewswire Inc.MiNK Therapeutics Announces Virtual Annual Shareholders MeetingNASDAQ:INKTMiNK Therapeutics Inc
02/06/202318:43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INKTMiNK Therapeutics Inc
26/05/202316:31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:INKTMiNK Therapeutics Inc
26/05/202316:05Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:INKTMiNK Therapeutics Inc
22/05/202307:30GlobeNewswire Inc.MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International ConferenceNASDAQ:INKTMiNK Therapeutics Inc
18/05/202307:30GlobeNewswire Inc.MiNK's Novel FAP-CAR-iNKT Presented at ASGCTNASDAQ:INKTMiNK Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:INKT

Su Consulta Reciente

UNSW3
4CHANETH
4CHAN
LSE
QH98
Morg.st.b.v 25
TG
XDNE
Xtrackers IE Public
NASDAQ
ABAFIXX
Morgan Stanley Finance L...
OKEX
WRCUSDT
HUOB
WNXMBTC
Wrapped NXM
LSE
91TE
Newday Fund E27
NYSE
OKE
ONEOK
TSXV
BIG
Hercules Silver
LSE
FT19
Sg Issuer 32
LSE
45MD
Municplty.40
COIN
AZKUST
Alien ZK
USOTC
ROIUF
Route1 (PK)
LBNK
TEMUSDT
TempleCoin
BOV
F1TN34R
Fortinet
COIN
SILK2BTC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados